Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
66.69
+0.10 (+0.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
47
48
Next >
Can Faraday Future (FFIE) Stock Turn Its Cash Crunch Around?
August 16, 2022
Faraday Future (FFIE) stock is on the move Tuesday as investors react to news of a new funding agreement to keep the business going.
Via
InvestorPlace
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,400 Today
August 16, 2022
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.41% on an annualized basis producing an average annual return of 14.28%. Currently, Gilead Sciences has a market...
Via
Benzinga
SoftBank Just Gave Nu Holdings (NU) Stock a Big Boost
August 16, 2022
Nu Holdings (NU) stock is on the rise Tuesday as investors react to news of SoftBank (SFTBY) taking a stake in the banking company.
Via
InvestorPlace
What Is Going on With Gilead Sciences (GILD) Stock Today?
August 16, 2022
GILD stock is the focus of not just one but two news items today, and traders are trying to decide if they're bullish or bearish.
Via
InvestorPlace
After Surprise Overall Survival Data In Metastatic Breast Cancer, Gilead Takes Complete Rights To Trodelvy
August 16, 2022
Via
Benzinga
Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
August 15, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Bets $400M On Inflammatory Diseases Focused UK Based Firm
August 04, 2022
Via
Benzinga
Gilead Sciences' Q2 Beats Street View On Robust Oncology, HIV Product Sales
August 03, 2022
Via
Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 15, 2022
Via
Benzinga
Why Gilead Sciences Stock Jumped 5% Today
August 15, 2022
Gilead Sciences Inc (NASDAQ: GILD) shares closed higher Monday after the company announced statistically significant and clinically meaning
Via
Benzinga
Snap, Gilead Sciences And Some Other Big Stocks Moving Higher On Monday
August 15, 2022
Magic Empire Global Limited (NASDAQ: MEGL) shares climbed 80.9% to $14.87 on volatility following the company's IPO earlier this month.
Via
Benzinga
Gilead Shares Climb On Positive Interim Analysis From Late-Stage Breast Cancer Study
August 15, 2022
Gilead Sciences, Inc. (NASDAQ: GILD) announced positive results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3 TROPiCS-02 study evaluating...
Via
Benzinga
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
August 15, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Boosts 2022 Guidance On The Back Of Its Covid Treatment
August 02, 2022
The company now expects the intravenous drug to generate $2.5 billion in sales this year.
Via
Investor's Business Daily
7 Growth Stocks to Buy After a 20% Correction
August 15, 2022
These are among the best growth stocks to buy now. ADBE, AMD, GILD, LOW, MELI, MP, and PYPL are poised to benefit from strong trends in 2022.
Via
InvestorPlace
3 Best Funds for Aggressive Investors
August 11, 2022
These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year.
Via
InvestorPlace
Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
August 09, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
August 2022 Stock Considerations
August 04, 2022
A look at August stock considerations.
Via
Talk Markets
Gilead's Biktarvy Demonstrates High Efficacy In HIV/HBV Coinfection Patients
July 28, 2022
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Gilead Sciences to Acquire MiroBio
August 04, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Recession Investing: 5 High Yield Dividend Stocks For A Downturn
August 03, 2022
As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their...
Via
Benzinga
Gilead Sciences: Q2 Earnings Insights
August 02, 2022
Gilead Sciences (NASDAQ:GILD) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Gilead Sciences beat estimated...
Via
Benzinga
Gilead Sciences Announces Second Quarter 2022 Financial Results
August 02, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Australia's Central Bank Has Raised Its Interest Rate. Business Activity In Europe Is Falling
August 02, 2022
Australia's Central Bank raised its interest rate by 50 basis points to 1.85%. The Bank said in a statement that it attaches great importance to getting inflation back into the 2-3 percent range over...
Via
Talk Markets
Recap Of Thursday's Biotech Catalysts - End of The Day Summary
July 28, 2022
Via
Benzinga
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection
July 28, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
8 Dividend ETFs to Buy and Hold Forever
July 27, 2022
Dividend ETFs like these eight provide investors with a steady source of income while they wait for the stock market to recover.
Via
InvestorPlace
Recap Of Friday's Biotech Catalysts - End Of The Day Summary
July 22, 2022
Via
Benzinga
Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
July 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.